Literature DB >> 17373631

Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1.

S Maor1, M Z Papa, R I Yarden, E Friedman, Y Lerenthal, S W Lee, D Mayer, H Werner.   

Abstract

The insulin-like growth factors (IGFs) have a central role in mammary gland growth and differentiation as well as in breast cancer development. The BRCA1 gene encodes a pleiotropic protein that functions as a transcription factor. Germline BRCA1 mutations are associated with inherited predisposition to breast and ovarian cancer and confer a substantially increased risk for developing these neoplasms. Several lines of evidence led us to hypothesize that there is a functional interaction between the BRCA1 and IGF-I systems relevant to breast cancer biology. The present study tested the notion that BRCA1 gene expression is regulated by the IGF-I signaling pathway. Results of Western immunoblotting and RT-PCR analyses show that IGF-I stimulates BRCA1 protein and mRNA levels. Transient transfection experiments using BRCA1 promoter-luciferase reporter constructs reveal that IGF-I enhances BRCA1 promoter activity, suggesting that the effect of IGF-I is mediated at the transcriptional level. In addition, we provide evidence that the Sp1 zinc-finger protein is directly involved in BRCA1 gene transactivation. Combined, our data suggests that, at least part of the biological actions of IGF-I in mammary gland cells may be mediated through BRCA1. Dysregulated BRCA1 expression resulting from aberrant IGF signaling may have important consequences relevant to breast cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17373631     DOI: 10.1055/s-2007-970415

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  16 in total

1.  Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers.

Authors:  Susan L Neuhausen; Sean Brummel; Yuan Chun Ding; Linda Steele; Katherine L Nathanson; Susan Domchek; Timothy R Rebbeck; Christian F Singer; Georg Pfeiler; Henry T Lynch; Judy E Garber; Fergus Couch; Jeffrey N Weitzel; Andrew Godwin; Steven A Narod; Patricia A Ganz; Mary B Daly; Claudine Isaacs; Olufunmilayo I Olopade; Gail E Tomlinson; Wendy S Rubinstein; Nadine Tung; Joanne L Blum; Daniel L Gillen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-27       Impact factor: 4.254

2.  Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families.

Authors:  Patrizia Pasanisi; Eleonora Bruno; Elisabetta Venturelli; Siranoush Manoukian; Monica Barile; Bernard Peissel; Clelia De Giacomi; Bernardo Bonanni; Jacopo Berrino; Franco Berrino
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

3.  Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function.

Authors:  Irene Guendel; Lawrence Carpio; Caitlin Pedati; Arnold Schwartz; Christine Teal; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

4.  Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.

Authors:  Hagit Schayek; Kathy Haugk; Shihua Sun; Lawrence D True; Stephen R Plymate; Haim Werner
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

5.  A randomized controlled trial of diet and physical activity in BRCA mutation carriers.

Authors:  P Pasanisi; E Bruno; S Manoukian; F Berrino
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

6.  Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.

Authors:  Oreekha Amin; Marie-Claude Beauchamp; Paul Abou Nader; Ido Laskov; Sanaa Iqbal; Charles-André Philip; Amber Yasmeen; Walter H Gotlieb
Journal:  BMC Cancer       Date:  2015-10-29       Impact factor: 4.430

Review 7.  Insulin-like growth factor-1 signaling in renal cell carcinoma.

Authors:  Adam F Tracz; Cezary Szczylik; Camillo Porta; Anna M Czarnecka
Journal:  BMC Cancer       Date:  2016-07-12       Impact factor: 4.430

8.  Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation.

Authors:  Neng Wang; Zhiyu Wang; Yu Wang; Xiaoming Xie; Jiangang Shen; Cheng Peng; Jieshu You; Fu Peng; Hailin Tang; Xinyuan Guan; Jianping Chen
Journal:  Oncotarget       Date:  2015

Review 9.  Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways.

Authors:  Haim Werner; Rive Sarfstein; Derek LeRoith; Ilan Bruchim
Journal:  Front Oncol       Date:  2016-06-23       Impact factor: 6.244

10.  Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.

Authors:  Charles-André Philip; Ido Laskov; Marie-Claude Beauchamp; Maud Marques; Oreekha Amin; Joanna Bitharas; Roy Kessous; Liron Kogan; Tahira Baloch; Walter H Gotlieb; Amber Yasmeen
Journal:  BMC Cancer       Date:  2017-09-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.